Craig C. Hopkinson - 23 Feb 2026 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
23 Feb 2026
Net transactions value
-$109,897
Form type
4
Filing time
25 Feb 2026, 17:46:04 UTC
Previous filing
20 Feb 2026
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopkinson Craig C. EVP R&D, Chief Medical Officer 900 WINTER ST., WALTHAM /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson 25 Feb 2026 0001730048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +7,689 +9% 92,986 23 Feb 2026 Direct F1
transaction ALKS Ordinary Shares Tax liability $109,897 -3,414 -3.7% $32.19 89,572 23 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -7,689 -50% 7,690 23 Feb 2026 Ordinary Shares 7,689 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.